Intellia Therapeutics Inc (NASDAQ: NTLA) on Monday, plunged -4.00% from the previous trading day, before settling in for the closing price of $10.99. Within the past 52 weeks, NTLA’s price has moved between $9.25 and $34.87.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 4.71% over the past five years. The company achieved an average annual earnings per share of 1.99%. With a float of $99.72 million, this company’s outstanding shares have now reached $101.80 million.
Let’s look at the performance matrix of the company that is accounted for 526 employees. In terms of profitability, gross margin is 82.41%, operating margin of -1247.99%, and the pretax margin is -1212.19%.
Intellia Therapeutics Inc (NTLA) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Intellia Therapeutics Inc is 2.09%, while institutional ownership is 92.45%. The most recent insider transaction that took place on Jan 03 ’25, was worth 16,711. In this transaction VP, Chief Accounting Officer of this company sold 1,372 shares at a rate of $12.18, taking the stock ownership to the 45,640 shares. Before that another transaction happened on Jan 03 ’25, when Company’s EVP, General Counsel sold 7,074 for $12.18, making the entire transaction worth $86,161. This insider now owns 74,497 shares in total.
Intellia Therapeutics Inc (NTLA) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 1.99% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.76% during the next five years compared to -22.30% drop over the previous five years of trading.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
Intellia Therapeutics Inc (NTLA) is currently performing well based on its current performance indicators. A quick ratio of 6.73 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 24.94.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.45, a number that is poised to hit -1.33 in the next quarter and is forecasted to reach -5.13 in one year’s time.
Technical Analysis of Intellia Therapeutics Inc (NTLA)
Intellia Therapeutics Inc (NASDAQ: NTLA) saw its 5-day average volume 3.17 million, a negative change from its year-to-date volume of 3.31 million. As of the previous 9 days, the stock’s Stochastic %D was 77.04%. Additionally, its Average True Range was 0.79.
During the past 100 days, Intellia Therapeutics Inc’s (NTLA) raw stochastic average was set at 8.96%, which indicates a significant decrease from 31.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 92.98% in the past 14 days, which was higher than the 73.64% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.86, while its 200-day Moving Average is $19.85. Nevertheless, the first resistance level for the watch stands at $10.85 in the near term. At $11.14, the stock is likely to face the second major resistance level. The third major resistance level sits at $11.51. If the price goes on to break the first support level at $10.18, it is likely to go to the next support level at $9.81. Assuming the price breaks the second support level, the third support level stands at $9.52.
Intellia Therapeutics Inc (NASDAQ: NTLA) Key Stats
Market capitalization of the company is 1.07 billion based on 101,849K outstanding shares. Right now, sales total 36,280 K and income totals -481,190 K. The company made 9,110 K in profit during its latest quarter, and -135,710 K in sales during its previous quarter.
